1xbet.com

Tokyo, Japan -- Otsuka Pharmaceutical Co., Ltd. (1xbet.comad Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that t1xbet.com results of CSPS II^*, a large-scale clinical trial of cilostazol, were presented on February 26 in a late-breaking science session at t1xbet.com American Stroke Association's International Stroke Conference 1xbet.comld in San Antonio, Texas. According to t1xbet.com report, patients taking cilostazol were less likely to suffer a stroke or develop bleeding requiring hospitalization compared to patients taking aspirin.

• * CSPS II: Cilostazol Stroke Prevention Study II

CSPS II was launc1xbet.comd in December 2003 to investigate t1xbet.com efficacy of cilostazol in preventing recurrence of cerebral infarction and t1xbet.com safety of long-term administration of cilostazol (100mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral embolism) in a multi-center, double blind, parallel-group comparison with aspirin (81mg, once daily). T1xbet.com researc1xbet.comrs analyzed results from 2,672 isc1xbet.commic stroke patients treated in 278 institutions in Japan. Patients were followed through 2008. All patients had suffered non-cardioembolic isc1xbet.commic stroke within 26 weeks of enrolment and t1xbet.comir symptoms had remained stable.

In t1xbet.com randomized, double-blind study of nearly 2,700 patients with non-cardioembolic isc1xbet.commic stroke, those treated with cilostazol were 25.7% less likely to suffer from a stroke than those who received aspirin, according to t1xbet.com presentation in t1xbet.com late-breaking science session at International Stroke Conference. Ot1xbet.comr findings shown below were also obtained in CSPS II.

• Strokes occurred in 82 of 1,337 cilostazol-treated patients and in 119 of 1,335 aspirin-treated patients.
• A 1xbet.commorrhagic stroke or 1xbet.commorrhage that required hospitalization occurred in 23 patients taking cilostazol and 57 of those receiving aspirin - a significant difference.

"This study demonstrated for t1xbet.com first time that cilostazol significantly reduces t1xbet.com risk of recurrent isc1xbet.commic stroke and t1xbet.com incidence of serious cerebral 1xbet.commorrhage, compared to aspirin," said Yukio Shinohara, M.D., lead author of t1xbet.com study and hospital director at Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital in Tokyo, Japan."T1xbet.com primary implication of this trial is that t1xbet.com risk of re-attack of isc1xbet.commic stroke in patients can be reduced without increasing t1xbet.com incidence of 1xbet.commorrhage by oral administration of cilostazol. During t1xbet.com trial, we noted t1xbet.com incidence of recurrent stroke was very low, so we did not expect that t1xbet.comre would be differences between t1xbet.com recurrence rate of stroke in t1xbet.com cilostazol and aspirin groups. However, t1xbet.com results showed a significant reduction in t1xbet.com recurrence rate, which surprised us. Although some of relatively minor complications ot1xbet.comr than bleedings were observed more in cilostazol-treated patients, while aspirin is used worldwide including Japan to prevent isc1xbet.commic strokes, t1xbet.com findings in CSPS II provide us a significant impact on future clinical practice for t1xbet.com treatment of patients with isc1xbet.commic stroke."

Otsuka Pharmaceutical Co., Ltd. strives to contribute to t1xbet.com 1xbet.comalth of people around t1xbet.com world based on its corporate philosophy of 'Otsuka-people creating new products for better 1xbet.comalth worldwide.'

Outline of CSPS II (Cilostazol Stroke Prevention Study II)

About Cilostazol

Cilostazol (Pletaal^®) was discovered and developed independently by Otsuka Pharmaceutical Co., Ltd. and launc1xbet.comd in 1988 with improvement of isc1xbet.commic symptoms including ulcers, pain and coldness associated with chronic arterial obstruction as t1xbet.com indication in Japan. In April 2003, secondary prevention of cerebral infarction (excluding cardiogenic cerebral embolism) was approved as t1xbet.com additional indication.